Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus FEXOFENADINE HYDROCHLORIDE HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus FEXOFENADINE HYDROCHLORIDE HIVES.
BENYLIN vs FEXOFENADINE HYDROCHLORIDE HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
60 mg orally twice daily or 180 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%).
Category C
Category A/B
Antihistamine
Antihistamine